{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:31:47Z","timestamp":1791919907446,"version":"4.3.4"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide. Platinum-based chemotherapy is standard-of-care but has limitations including toxicity and resistance. Metal complexes of gold, ruthenium, and other metals have emerged as promising alternatives. This review provides a comprehensive analysis of metallodrugs for NSCLC. Bibliometric analysis reveals growing interest in elucidating mechanisms, developing targeted therapies, and synergistic combinations. Classification of metallodrugs highlights platinum, gold, and ruthenium compounds, as well as emerging metals. Diverse mechanisms include DNA damage, redox modulation, and immunomodulation. Preclinical studies demonstrate cytotoxicity and antitumor effects\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    , providing proof-of-concept. Clinical trials indicate platinums have utility but resistance remains problematic. Non-platinum metallodrugs exhibit favorable safety but modest single agent efficacy to date. Drug delivery approaches like nanoparticles show potential to enhance therapeutic index. Future directions include optimization of metal-based complexes, elucidation of resistance mechanisms, biomarker development, and combination therapies to fully realize the promise of metallodrugs for NSCLC.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1242488","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T12:27:03Z","timestamp":1693484823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes"],"prefix":"10.3389","volume":"14","author":[{"given":"Xianzhi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"12888","DOI":"10.1039\/d0sc04082g","article-title":"Metallodrugs are unique: opportunities and challenges of discovery and development","volume":"11","author":"Anthony","year":"2020","journal-title":"Chem. Sci."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01012-5","article-title":"The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo","volume":"5","author":"Asperti","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1039\/c0dt01816c","article-title":"Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs","volume":"40","author":"Bergamo","year":"2011","journal-title":"Dalton Trans."},{"key":"B5","doi-asserted-by":"publisher","first-page":"14852","DOI":"10.1021\/acs.inorgchem.8b02604","article-title":"New variations on the theme of gold(III) C\u2227N\u2227N cyclometalated complexes as anticancer agents: synthesis and biological characterization","volume":"57","author":"Carboni","year":"2018","journal-title":"Inorg. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"590970","DOI":"10.3389\/fonc.2020.590970","article-title":"Metabolic aspects of palladium(II) potential anti-cancer drugs","volume":"10","author":"Carneiro","year":"2020","journal-title":"Front. Oncol."},{"key":"B63","unstructured":"RK-ES001A\n            ClinicalTrials"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5207","DOI":"10.3390\/molecules27165207","article-title":"Anti-cancer effects of auranofin in human lung cancer cells by increasing intracellular ROS levels and depleting GSH levels","volume":"27","author":"Cui","year":"2022","journal-title":"Molecules"},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.freeradbiomed.2021.10.020","article-title":"Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer","volume":"177","author":"Delgobo","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"B9","article-title":"Carboplatin","volume-title":"StatPearls. Treasure island (FL)","author":"Devanabanda","year":""},{"key":"B10","article-title":"Oxaliplatin","volume-title":"StatPearls. Treasure island (FL)","author":"Devanabanda","year":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jinorgbio.2018.02.019","article-title":"Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNAPhe","volume":"182","author":"Dwyer","year":"2018","journal-title":"J. Inorg. Biochem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/jacs.2c11111","article-title":"Ruthenium(II) polypyridyl complexes as FRET donors: structure- and sequence-selective DNA-binding and anticancer properties","volume":"145","author":"Elgar","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00775-018-1546-8","article-title":"A heterometallic ruthenium-gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer","volume":"23","author":"Elie","year":"2018","journal-title":"J. Biol. Inorg. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.3390\/molecules27113504","article-title":"Casiopeinas of third generations: synthesis, characterization, cytotoxic activity and structure-activity relationships of mixed chelate compounds with bioactive secondary ligands","volume":"27","author":"Figueroa-DePaz","year":"2022","journal-title":"Molecules"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1039\/c9sc06460e","article-title":"Metal complexes as a promising source for new antibiotics","volume":"11","author":"Frei","year":"2020","journal-title":"Chem. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101949","DOI":"10.1016\/j.redox.2021.101949","article-title":"Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer","volume":"42","author":"Freire Boullosa","year":"2021","journal-title":"Redox Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2171158","DOI":"10.1080\/10717544.2023.2171158","article-title":"Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy","volume":"30","author":"Fu","year":"2023","journal-title":"Drug Deliv."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7211","DOI":"10.1007\/s00216-018-1328-8","article-title":"Critical assessment of different methods for quantitative measurement of metallodrug-protein associations","volume":"410","author":"Galvez","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1039\/c2dt12083f","article-title":"Ruthenium(II) arene complexes with chelating chloroquine analogue ligands: synthesis, characterization and in vitro antimalarial activity","volume":"41","author":"Glans","year":"2012","journal-title":"Dalton Trans."},{"key":"B21","doi-asserted-by":"publisher","first-page":"15312","DOI":"10.1021\/acs.inorgchem.0c02298","article-title":"N-heterocyclic carbene gold(I) complexes: mechanism of the ligand scrambling reaction and their oxidation to gold(III) in aqueous solutions","volume":"59","author":"Goetzfried","year":"2020","journal-title":"Inorg. Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.3390\/ijms22115814","article-title":"Genomic characterization of cisplatin response uncovers priming of cisplatin-induced genes in a resistant cell line","volume":"22","author":"Golan Berman","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1038\/s41467-022-31859-3","article-title":"A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer","volume":"13","author":"Goldberg","year":"2022","journal-title":"Nat. Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/cam4.826","article-title":"Antimetastatic activity of novel ruthenium (III) pyridine complexes","volume":"5","author":"Gu","year":"2016","journal-title":"Cancer Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1039\/d1dt02988f","article-title":"Terpyridine copper(II) complexes as potential anticancer agents by inhibiting cell proliferation, blocking the cell cycle and inducing apoptosis in BEL-7402 cells","volume":"51","author":"Gu","year":"2022","journal-title":"Dalton Trans."},{"key":"B26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00775-023-01998-z","article-title":"Steric hindrance, ligand ejection and associated photocytotoxic properties of ruthenium(II) polypyridyl complexes","volume":"28","author":"Herrera-Ram\u00edrez","year":"2023","journal-title":"J. Biol. Inorg. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1002\/1878-0261.12568","article-title":"Metabolomic, transcriptomic and genetic integrative analysis reveals important roles of adenosine diphosphate in haemostasis and platelet activation in non-small-cell lung cancer","volume":"13","author":"Hoang","year":"2019","journal-title":"Mol. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"876410","DOI":"10.3389\/fchem.2022.876410","article-title":"Ligand evolution in the photoactivatable platinum(IV) anticancer prodrugs","volume":"10","author":"Huang","year":"2022","journal-title":"Front. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00280-009-1188-1","article-title":"A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors","volume":"65","author":"Jameson","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B1","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3390\/molecules23102571","article-title":"Organotin(IV) dithiocarbamate complexes: chemistry and biological activity","volume":"23","author":"Jo","year":"2018","journal-title":"Molecules"},{"key":"B33","doi-asserted-by":"publisher","first-page":"035101","DOI":"10.1088\/1361-6528\/ac990e","article-title":"Tumor microenvironment and redox dual stimuli-responsive polymeric nanoparticles for the effective cisplatin-based cancer chemotherapy","volume":"34","author":"Jia","year":"2022","journal-title":"Nanotechnology"},{"key":"B34","unstructured":"Auranofin inhibition of thioredoxin reductase in a preclinical model of small cell lung cancer\n            JohnsonS. S.\n            LiuD.\n            EwaldJ. T.\n          2023"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"10369","DOI":"10.1039\/d1dt01604k","article-title":"GSH-resistant and highly cytoselective ruthenium(II)-p-cymene-(imidazo[4,5-f] [1,10]phenanthrolin-2-yl)phenol complexes as potential anticancer agents","volume":"50","author":"Kar","year":"2021","journal-title":"Dalton Trans."},{"key":"B37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/toxsci\/kfab041","article-title":"Anticancer activity and in vitro to in vivo mechanistic recapitulation of novel ruthenium-based metallodrugs in the zebrafish model","volume":"182","author":"Karas","year":"2021","journal-title":"Toxicol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2018.09.014","article-title":"Phase I\/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer","volume":"125","author":"Kawano","year":"2018","journal-title":"Lung Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2147\/IJN.S129274","article-title":"Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells","volume":"12","author":"Ke","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1039\/d2md00304j","article-title":"Anticancer evaluation of new organometallic ruthenium(ii) flavone complexes","volume":"14","author":"Khater","year":"2022","journal-title":"RSC Med. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"7467","DOI":"10.1039\/d1sc01418h","article-title":"Anticancer gold(iii)-bisphosphine complex alters the mitochondrial electron transport chain to induce in vivo tumor inhibition","volume":"12","author":"Kim","year":"2021","journal-title":"Chem. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"23943","DOI":"10.1038\/s41598-021-03352-2","article-title":"Evaluation of anticancer activity in vitro of a stable copper(I) complex with phosphine-peptide conjugate","volume":"11","author":"Komarnicka","year":"2021","journal-title":"Sci. Rep."},{"key":"B43","unstructured":"KP1339\n            ClinicalTrials"},{"key":"B44","doi-asserted-by":"publisher","first-page":"13524","DOI":"10.1002\/anie.201608094","article-title":"A macrocyclic ruthenium(III) complex inhibits angiogenesis with down-regulation of vascular endothelial growth factor receptor-2 and suppresses tumor growth in vivo","volume":"55","author":"Kwong","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B45","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neo.2014.12.008","article-title":"Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1\u03b1 in EGFR-mutated lung cancer in vitro and in vivo","volume":"17","author":"Lee","year":"2015","journal-title":"Neoplasia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10637-014-0179-1","article-title":"Phase I\/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy","volume":"33","author":"Leijen","year":"2015","journal-title":"Invest. New Drugs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J. Clin. Invest."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/biom12091319","article-title":"Controversial role of transferrin in the transport of ruthenium anticancer drugs","volume":"12","author":"Levina","year":"2022","journal-title":"Biomolecules"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.1038\/s41467-022-35022-w","article-title":"A nuclease-mimetic platinum nanozyme induces concurrent DNA platination and oxidative cleavage to overcome cancer drug resistance","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"114312","DOI":"10.1016\/j.ejmech.2022.114312","article-title":"Anticancer activity of ruthenium(II) plumbagin complexes with polypyridyl as ancillary ligands via inhibiting energy metabolism and GADD45A-mediated cell cycle arrest","volume":"236","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"B51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jinorgbio.2018.11.011","article-title":"Triphenyltin(IV) acylhydrazone compounds: synthesis, structure and bioactivity","volume":"191","author":"Liu","year":"2019","journal-title":"J. Inorg. Biochem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1038\/s41467-022-29969-z","article-title":"An osmium-peroxo complex for photoactive therapy of hypoxic tumors","volume":"13","author":"Lu","year":"2022","journal-title":"Nat. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1039\/d2tb01150f","article-title":"Reversal of cisplatin chemotherapy resistance by glutathione-resistant copper-based nanomedicine via cuproptosis","volume":"10","author":"Lu","year":"2022","journal-title":"J. Mater Chem. B"},{"key":"B54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12274-018-2210-x","article-title":"A theranostic agent for cancer therapy and imaging in the second near-infrared window","volume":"12","author":"Ma","year":"2019","journal-title":"Nano Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/nano12071221","article-title":"Intranasal administration of catechol-based Pt(IV) coordination polymer nanoparticles for glioblastoma therapy","volume":"12","author":"Mao","year":"2022","journal-title":"Nanomater. (Basel)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1039\/c9dt00866g","article-title":"Discovery of high in vitro and in vivo antitumor activities of organometallic ruthenium(ii)-arene complexes with 5,7-dihalogenated-2-methyl-8-quinolinol","volume":"48","author":"Meng","year":"2019","journal-title":"Dalton Trans."},{"key":"B58","doi-asserted-by":"publisher","first-page":"6942","DOI":"10.1002\/chem.201605801","article-title":"Protein metalation by anticancer metallodrugs: a joint esi ms and xrd investigative strategy","volume":"23","author":"Merlino","year":"2017","journal-title":"Chemistry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fchem.2020.00209","article-title":"Investigations on the anticancer potential of benzothiazole-based metallacycles","volume":"8","author":"Mokesch","year":"2020","journal-title":"Front. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"111207","DOI":"10.1016\/j.jinorgbio.2020.111207","article-title":"Synthesis, characterization and in vitro biological evaluation of novel organotin(IV) compounds with derivatives of 2-(5-arylidene-2,4-dioxothiazolidin-3-yl)propanoic acid","volume":"211","author":"Panteli\u0107","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1021\/acs.accounts.7b00301","article-title":"Comparing strategies in the design of responsive contrast agents for magnetic resonance imaging: a case study with copper and zinc","volume":"51","author":"Pierre","year":"2018","journal-title":"Acc. Chem. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2174\/1871520621666210712090017","article-title":"Consequences of extracellular matrix remodeling in headway and metastasis of cancer along with novel immunotherapies: a great promise for future endeavor","volume":"22","author":"Ray","year":"2022","journal-title":"Anticancer Agents Med. Chem."},{"key":"B64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcis.2021.08.153","article-title":"Co-loading of doxorubicin and iron oxide nanocubes in polycaprolactone fibers for combining Magneto-Thermal and chemotherapeutic effects on cancer cells","volume":"607","author":"Serio","year":"2022","journal-title":"J. Colloid Interface Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1021\/acs.nanolett.7b00132","article-title":"A liposome encapsulated ruthenium polypyridine complex as a theranostic platform for triple-negative breast cancer","volume":"17","author":"Shen","year":"2017","journal-title":"Nano Lett."},{"key":"B66","doi-asserted-by":"publisher","first-page":"8949450","DOI":"10.1155\/2018\/8949450","article-title":"Ex vivo cardiotoxicity of antineoplastic casiopeinas is mediated through energetic dysfunction and triggered mitochondrial-dependent apoptosis","volume":"2018","author":"Silva-Platas","year":"2018","journal-title":"Oxid. Med. Cell Longev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B68","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/JEP.S267383","article-title":"Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy","volume":"13","author":"Tchounwou","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3390\/pharmaceutics14061293","article-title":"Ruthenium(II)-Cyclopentadienyl-Derived complexes as new emerging anti-colorectal cancer drugs","volume":"14","author":"Teixeira-Guedes","year":"2022","journal-title":"Pharmaceutics"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1021\/acsinfecdis.9b00505","article-title":"Preclinical gold complexes as oral drug candidates to treat leishmaniasis are potent trypanothione reductase inhibitors","volume":"6","author":"Tunes","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"8578","DOI":"10.1039\/c9dt00250b","article-title":"A new class of prophylactic metallo-antibiotic possessing potent anti-cancer and anti-microbial properties","volume":"48","author":"Ude","year":"2019","journal-title":"Dalton Trans."},{"key":"B72","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.3390\/ijms22147379","article-title":"Cisplatin resistance and redox-metabolic vulnerability: a second alteration","volume":"22","author":"Wangpaichitr","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1038\/s41467-022-32474-y","article-title":"Pro-oxidant response and accelerated ferroptosis caused by synergetic Au(I) release in hypercarbon-centered gold(I) cluster prodrugs","volume":"13","author":"Xiao","year":"2022","journal-title":"Nat. Commun."},{"key":"B74","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/17425247.2021.1832989","article-title":"Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers)","volume":"18","author":"Yadav","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"B75","doi-asserted-by":"publisher","first-page":"355101","DOI":"10.1088\/1361-6528\/ab9395","article-title":"Folic acid-modified methotrexate-conjugated gold nanoparticles as nano-sized trojans for drug delivery to folate receptor-positive cancer cells","volume":"31","author":"Y\u00fccel","year":"2020","journal-title":"Nanotechnology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"979951","DOI":"10.3389\/fphar.2022.979951","article-title":"Organometallic gold(I) and gold(III) complexes for lung cancer treatment","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"120869","DOI":"10.1016\/j.jorganchem.2019.07.020","article-title":"Ruthenium arene complex induces cell cycle arrest and apoptosis through activation of P53-mediated signaling pathways","volume":"898","author":"Zhao","year":"2019","journal-title":"J. Organomet. Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/s41557-023-01199-w","article-title":"In vivo metallophilic self-assembly of a light-activated anticancer drug","volume":"15","author":"Zhou","year":"2023","journal-title":"Nat. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1242488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T12:27:07Z","timestamp":1693484827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1242488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":78,"alternative-id":["10.3389\/fphar.2023.1242488"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1242488","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"article-number":"1242488"}}